Similar articles

• Difelikefalin: First Approval.

  Deeks ED. Deeks ED. Drugs. 2021 Nov;81(16):1937-1944. doi: 10.1007/s40265-021-01619-6. Drugs. 2021. PMID: 34674115 Review.
• Clinically meaningful change in itch intensity scores: An evaluation in patients with chronic kidney disease-associated pruritus.

  Vernon M, Ständer S, Munera C, Spencer RH, Menzaghi F. Vernon M, et al. J Am Acad Dermatol. 2021 Apr;84(4):1132-1134. doi: 10.1016/j.jaad.2020.06.991. Epub 2020 Jun 27. J Am Acad Dermatol. 2021. PMID: 32603719 Clinical Trial. No abstract available.
• Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus.

  Fugal J, Serpa SM. Fugal J, et al. Ann Pharmacother. 2023 Apr;57(4):480-488. doi: 10.1177/10600280221115889. Epub 2022 Aug 9. Ann Pharmacother. 2023. PMID: 35942600 Review.
• Newer and Safer Kappa-Opioid Agonist for Your Patients With Uremic Pruritus.

  Lagacé F, Jfri A, Litvinov IV, Netchiporouk E. Lagacé F, et al. J Cutan Med Surg. 2020 Sep/Oct;24(5):525-526. doi: 10.1177/1203475420926989. Epub 2020 May 19. J Cutan Med Surg. 2020. PMID: 32426990 No abstract available.
• Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study.

  Solak Y, Biyik Z, Atalay H, Gaipov A, Guney F, Turk S, Covic A, Goldsmith D, Kanbay M. Solak Y, et al. Nephrology (Carlton). 2012 Nov;17(8):710-7. doi: 10.1111/j.1440-1797.2012.01655.x. Nephrology (Carlton). 2012. PMID: 22909343 Clinical Trial.